DiaMedica Therapeutics Inc.
DMAC
$6.59
$0.050.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.76% | 21.66% | 28.32% | 17.49% | 8.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.71% | 26.31% | 28.92% | 39.37% | 40.52% |
| Operating Income | -24.71% | -26.31% | -28.92% | -39.37% | -40.52% |
| Income Before Tax | -26.93% | -30.04% | -34.10% | -47.26% | -48.81% |
| Income Tax Expenses | 7.14% | 0.00% | -6.67% | -37.21% | -34.88% |
| Earnings from Continuing Operations | -26.91% | -30.00% | -34.05% | -47.09% | -48.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.91% | -30.00% | -34.05% | -47.09% | -48.63% |
| EBIT | -24.71% | -26.31% | -28.92% | -39.37% | -40.52% |
| EBITDA | -24.69% | -26.34% | -28.95% | -39.40% | -40.57% |
| EPS Basic | -3.58% | -9.37% | -16.27% | -29.78% | -31.83% |
| Normalized Basic EPS | -3.64% | -9.45% | -16.36% | -29.94% | -31.97% |
| EPS Diluted | -3.58% | -9.37% | -16.27% | -29.78% | -31.83% |
| Normalized Diluted EPS | -3.64% | -9.45% | -16.36% | -29.94% | -31.97% |
| Average Basic Shares Outstanding | 22.39% | 19.42% | 16.25% | 13.68% | 12.74% |
| Average Diluted Shares Outstanding | 22.39% | 19.42% | 16.25% | 13.68% | 12.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |